Profile of Danielle Maciorowski, PharmD - Pharmacy Educator

March 2025 Family Times Educator Profile

1. What inspired you to pursue a career in pharmacy, particularly in hematology and oncology—and what ultimately led you to join Hematology-Oncology Associates of CNY (HOA)?

Pactical Meditation March 13

Practical Meditation

Develop independence in meditation!

Whether you're new to meditation or looking to deepen your practice, this class offers simple, practical techniques you can use immediately. In this session, you'll explore:

Body Awareness, Points of Focus and Your Own Sound as tools to help quiet both the internal and external world.

November 2025

Sun Mon Tue Wed Thu Fri Sat
26
27
28
29
30
31
1
 
 
 
 
 
 
 
2
3
4
5
6
7
8
 
 
 
 
 
 
 
9
10
11
12
13
14
15
 
 
 
 
 
 
 
16
17
18
19
20
21
22
 
 
 
 
 
 
 
23
24
25
26
27
28
29
 
 
 
 
 
 
 
30
1
2
3
4
5
6
 
 
 
 
 
 
 

Cancer Q&A with HOA: Genetic testing for cancer

Patient Newsletter 2025 February

Multiple Myeloma, EAA173

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.

Breast, Personalis, 01-PS-001

ClinicalTrials.gov ID NCT06230185

A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.

Patient Newsletter 2025 January

HOA Appoints New CEO Jennifer Pichoske

Hematology-Oncology Associates of CNY (HOA) has appointed Jennifer Pichoske, MS, EMBA, AOCNP as Chief Executive Officer effective February 15, 2025. She succeeds Maryann Roefaro, MS, CEO since 2002, who is retiring.

HOA Appoints New CEO as of Feb. 15, 2025

Pages